 | • レポートコード：TPM-DJ146 • 出版社/出版日：Transparency Market Research / 2019年3月12日 • レポート形態：英文、PDF、203ページ • 納品方法：Eメール • 産業分類：製薬 |
| Single User | ￥857,660 (USD5,795) | ▷ お問い合わせ |
| Multi User | ￥1,301,660 (USD8,795) | ▷ お問い合わせ |
| Global Site License | ￥1,745,660 (USD11,795) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 本資料は、組換え型血漿タンパク質治療薬の世界市場について調べ、組換え型血漿タンパク質治療薬の市場規模、市場動向、市場シェア、市場環境、市場予測、関連企業情報などをまとめました。 |
Global Recombinant Plasma Protein Therapeutics Market: Overview
This report analyzes the current and future scenario of the global recombinant plasma protein therapeutics market. Rise in focus on the treatment of rare diseases, increase in the number of cases with hemophilia A & hemophilia B, and surge in awareness about diagnosis and treatment of hemophilia and other bleeding disorders are major factors that are anticipated to drive the market during the forecast period. Moreover, increase in the number of healthcare providers prescribing recombinant plasma protein therapies for hemophilia A and rapid adoption of genetic engineering technologies in healthcare for the development of new therapeutics are also estimated to fuel the market during the forecast period.
The global recombinant plasma protein therapeutics market report comprises an elaborate executive summary, which includes a snapshot that provides information about various segments of the market. It also provides information and data analysis of the global market with respect to the segments based on drug class, cell line, indication, and region. A detailed qualitative analysis of drivers and restraints of the market, and opportunities has been provided in the overview section. Additionally, the section comprises competitive matrix and company profiles along with business overview to understand the competitive landscape in the market. This section of the report also provides market attractiveness analysis by region and market share analysis by key players, thereby presenting a thorough analysis of the overall competitive scenario in the global recombinant plasma protein therapeutics market.
New product launch and FDA approvals are also important factors that are expected to boost the market across the globe. For instance, in April 2018, Shire received FDA approval for VONVENDI recombinant von Willebrand factor indicated for perioperative management of bleeding in patients with von Willebrand disease (VWD)
Global Recombinant Plasma Protein Therapeutics Market: Key Segments
The global recombinant plasma protein therapeutics market has been segmented based on drug class, cell line, and indication. Based on drug class, the market has been classified into recombinant coagulation factors and human C1 esterase inhibitor. The recombinant coagulation factors sub-segment has been further sub-segmented into recombinant coagulation factor VIII, recombinant coagulation factor IX, recombinant coagulation factor VIIa, and others. The recombinant coagulation factor IX sub-segment is anticipated to expand at a rapid pace during the forecast period, due to an increase in the demand for recombinant coagulation factor IX for the treatment of hemophilia B. In terms of cell line, the market has been categorized into Chinese hamster ovary (CHO) cell line, baby hamster kidney (BHK) cell line, human embryonic kidney (HEK) cell line, and others. Based on indication, the market has been segmented into hemophilia A, hemophilia B, Von Willebrand disease, and others. The market size and forecast for each of these segments have been provided for the period from 2016 to 2026, along with their respective CAGRs for the forecast period from 2018 to 2026, considering 2017 as the base year.
Global Recombinant Plasma Protein Therapeutics Market: Regional Outlook
In terms of region, the global recombinant plasma protein therapeutics market has been segmented into North America (U.S. and Canada), Europe (U.K., Germany, France, Spain, Italy, and Rest of Europe), Asia Pacific (India, China, Japan, Australia & New Zealand, and Rest of Asia Pacific), Latin America (Brazil, Mexico, and Rest of Latin America), and Middle East & Africa (South Africa, GCC Countries, Israel, and Rest of Middle East & Africa). The market size and forecast for each of these regions and the mentioned countries/sub-regions have been provided for the period from 2016 to 2026, along with their respective CAGRs for the forecast period from 2018 to 2026, considering 2017 as the base year. The research study also covers the competitive scenario in these regions.
Companies Mentioned in Report
The report also profiles major players operating in the global recombinant plasma protein therapeutics market based on various attributes such as company overview, financial overview, product portfolio, business strategies, and recent developments. Key players profiled in the market report include CSL Limited, Shire (Takeda Pharmaceutical Company Limited), Octapharma, Novo Nordisk A/S, Bayer AG, Bioverativ Therapeutics, Inc. (Sanofi), Aptevo Therapeutics, Pharming Group NV, and Pfizer Inc.
The global recombinant plasma protein therapeutics market has been segmented as below:
Global Recombinant Plasma Protein Therapeutics Market, by Drug Class
Recombinant Coagulation Factors
Recombinant Coagulation Factor VIII
Recombinant Coagulation Factor IX
Recombinant Coagulation Factor VIIa
Others
Human C1 Esterase Inhibitor
Global Recombinant Plasma Protein Therapeutics Market, by Cell Line
Chinese Hamster Ovary (CHO) Cell Line
Baby Hamster Kidney (BHK) Cell Line
Human Embryonic Kidney (HEK) Cell Line
Others
Global Recombinant Plasma Protein Therapeutics Market, by Indication
Hemophilia A
Hemophilia B
Von Willebrand Disease
Others
Global Recombinant Plasma Protein Therapeutics Market, by Region
North America
U.S.
Canada
Europe
Germany
U.K.
Italy
France
Spain
Rest of Europe
Asia Pacific
India
China
Japan
Australia & New Zealand
Rest of Asia Pacific
Latin America
Brazil
Mexico
Rest of Latin America
Middle East & Africa
GCC Countries
South Africa
Rest of Middle East & Africa
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary : Global Recombinant Plasma Protein Therapeutics Market
4. Market Overview
4.1. Introduction
4.1.1. Product Definition
4.1.2. Industry Evolution / Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.1.1 Shift from use of Plasma Derived Proteins to Recombinant Therapies
4.3.1.2 Rising Awareness about Rare Disease Management
4.3.1.3 Increasing Focus on Investments in Rare Disease
4.3.2. Restraints
4.3.2.1 High Cost of Treatment
4.3.2.2 Availability of Alternative Therapies
4.3.3. Opportunities
4.3.3.1 Growth Opportunities in Developing Markets
4.3.3.2 Strategic Approaches such as Partnership and Distribution Agreements
4.4. Global Recombinant Plasma Protein Therapeutics Market Analysis and Forecast, 2016–2026
5. Key Insights
5.1. New Product Launch and Regulatory Approvals
5.2. Key Mergers & Acquisitions
5.3. Regulatory Scenario by Region/Country
6. Global Recombinant Plasma Protein Therapeutics Market Analysis and Forecast, by Drug Class
6.1. Introduction & Definition
6.2. Key Findings / Developments
6.3. Global Recombinant Plasma Protein Therapeutics Market Value Forecast, by Drug Class, 2016–2026
6.3.1. Recombinant Coagulation Factors
6.3.1.1. Recombinant Coagulation Factor VIII
6.3.1.2. Recombinant Coagulation Factor IX
6.3.1.3. Recombinant Coagulation Factor VIIa
6.3.1.4. Others
6.3.2. Human C1 Esterase Inhibitor
6.4. Global Recombinant Plasma Protein Therapeutics Market Attractiveness, by Drug Class
7. Global Recombinant Plasma Protein Therapeutics Market Analysis and Forecast, by Cell Line
7.1. Introduction & Definition
7.2. Key Findings / Developments
7.3. Global Recombinant Plasma Protein Therapeutics Market Value Forecast, by Cell Line, 2016–2026
7.3.1. Chinese Hamster Ovary (CHO) Cell Line
7.3.2. Baby Hamster Kidney (BHK) Cell Line
7.3.3. Human Embryonic Kidney (HEK) Cell Line
7.3.4. Others
7.4. Global Recombinant Plasma Protein Therapeutics Market Attractiveness, by Cell Line
8. Global Recombinant Plasma Protein Therapeutics Market Analysis and Forecast, by Indication
8.1. Introduction & Definition
8.2. Key Findings / Developments
8.3. Global Recombinant Plasma Protein Therapeutics Market Value Forecast, by Indication, 2016–2026
8.3.1. Hemophilia A
8.3.2. Hemophilia B
8.3.3. Von Willebrand Disease
8.3.4. Others
8.4. Global Recombinant Plasma Protein Therapeutics Market Attractiveness, by Indication
9. Global Recombinant Plasma Protein Therapeutics Market Analysis and Forecast, by Region
9.1. Key Findings
9.2. Global Recombinant Plasma Protein Therapeutics Market Value Forecast, by Region
9.2.1. North America
9.2.2. Europe
9.2.3. Asia Pacific
9.2.4. Latin America
9.2.5. Middle East & Africa
9.3. Global Recombinant Plasma Protein Therapeutics Market Attractiveness, by Region
10. North America Recombinant Plasma Protein Therapeutics Market Analysis and Forecast
10.1. Introduction
10.1.1. Key Findings
10.2. North America Recombinant Plasma Protein Therapeutics Market Value Forecast, by Drug Class, 2016–2026
10.2.1. Recombinant Coagulation Factors
10.2.1.1. Recombinant Coagulation Factor VIII
10.2.1.2. Recombinant Coagulation Factor IX
10.2.1.3. Recombinant Coagulation Factor VIIa
10.2.1.4. Others
10.2.2. Human C1 Esterase Inhibitor
10.3. North America Recombinant Plasma Protein Therapeutics Market Value Forecast, by Cell Line, 2016–2026
10.3.1. Chinese Hamster Ovary (CHO) Cell Line
10.3.2. Baby Hamster Kidney (BHK) Cell Line
10.3.3. Human Embryonic Kidney (HEK) Cell Line
10.3.4. Others
10.4. North America Recombinant Plasma Protein Therapeutics Market Value Forecast, by Indication, 2016–2026
10.4.1. Hemophilia A
10.4.2. Hemophilia B
10.4.3. Von Willebrand Disease
10.4.4. Others
10.5. North America Recombinant Plasma Protein Therapeutics Market Value Forecast, by Country, 2016–2026
10.5.1. U.S.
10.5.2. Canada
10.6. North America Recombinant Plasma Protein Therapeutics Market Attractiveness Analysis
10.6.1. By Drug Class
10.6.2. By Cell Line
10.6.3. By Indication
10.6.4. By Country
11. Europe Recombinant Plasma Protein Therapeutics Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Europe Recombinant Plasma Protein Therapeutics Market Value Forecast, by Drug Class, 2016–2026
11.2.1. Recombinant Coagulation Factors
11.2.1.1. Recombinant Coagulation Factor VIII
11.2.1.2. Recombinant Coagulation Factor IX
11.2.1.3. Recombinant Coagulation Factor VIIa
11.2.1.4. Others
11.2.2. Human C1 Esterase Inhibitor
11.3. Europe Recombinant Plasma Protein Therapeutics Market Value Forecast, by Cell Line, 2016–2026
11.3.1. Chinese Hamster Ovary (CHO) Cell Line
11.3.2. Baby Hamster Kidney (BHK) Cell Line
11.3.3. Human Embryonic Kidney (HEK) Cell Line
11.3.4. Others
11.4. Europe Recombinant Plasma Protein Therapeutics Market Value Forecast, by Indication, 2016–2026
11.4.1. Hemophilia A
11.4.2. Hemophilia B
11.4.3. Von Willebrand Disease
11.4.4. Others
11.5. Europe Recombinant Plasma Protein Therapeutics Market Value Forecast, by Country/Sub-region, 2016–2026
11.5.1. Germany
11.5.2. U.K.
11.5.3. France
11.5.4. Spain
11.5.5. Italy
11.5.6. Rest of Europe
11.6. Europe Recombinant Plasma Protein Therapeutics Market Attractiveness Analysis
11.6.1. By Drug Class
11.6.2. By Cell Line
11.6.3. By Indication
11.6.4. By Country/Sub-region
12. Asia Pacific Recombinant Plasma Protein Therapeutics Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Asia Pacific Recombinant Plasma Protein Therapeutics Market Value Forecast, by Drug Class, 2016–2026
12.2.1. Recombinant Coagulation Factors
12.2.1.1. Recombinant Coagulation Factor VIII
12.2.1.2. Recombinant Coagulation Factor IX
12.2.1.3. Recombinant Coagulation Factor VIIa
12.2.1.4. Others
12.2.2. Human C1 Esterase Inhibitor
12.3. Asia Pacific Recombinant Plasma Protein Therapeutics Market Value Forecast, by Cell Line, 2016–2026
12.3.1. Chinese Hamster Ovary (CHO) Cell Line
12.3.2. Baby Hamster Kidney (BHK) Cell Line
12.3.3. Human Embryonic Kidney (HEK) Cell Line
12.3.4. Others
12.4. Asia Pacific Recombinant Plasma Protein Therapeutics Market Value Forecast, by Indication, 2016–2026
12.4.1. Hemophilia A
12.4.2. Hemophilia B
12.4.3. Von Willebrand Disease
12.4.4. Others
12.5. Asia Pacific Recombinant Plasma Protein Therapeutics Market Value Forecast, by Country/Sub-region, 2016–2026
12.5.1. China
12.5.2. Japan
12.5.3. India
12.5.4. Australia & New Zealand
12.5.5. Rest of Asia Pacific
12.6. Asia Pacific Recombinant Plasma Protein Therapeutics Market Attractiveness Analysis
12.6.1. By Drug Class
12.6.2. By Cell Line
12.6.3. By Indication
12.6.4. By Country/Sub-region
13. Latin America Recombinant Plasma Protein Therapeutics Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Latin America Recombinant Plasma Protein Therapeutics Market Value Forecast, by Drug Class, 2016–2026
13.2.1. Recombinant Coagulation Factors
13.2.1.1. Recombinant Coagulation Factor VIII
13.2.1.2. Recombinant Coagulation Factor IX
13.2.1.3. Recombinant Coagulation Factor VIIa
13.2.1.4. Others
13.2.2. Human C1 Esterase Inhibitor
13.3. Latin America Recombinant Plasma Protein Therapeutics Market Value Forecast, by Cell Line, 2016–2026
13.3.1. Chinese Hamster Ovary (CHO) Cell Line
13.3.2. Baby Hamster Kidney (BHK) Cell Line
13.3.3. Human Embryonic Kidney (HEK) Cell Line
13.3.4. Others
13.4. Latin America Recombinant Plasma Protein Therapeutics Market Value Forecast, by Indication, 2016–2026
13.4.1. Hemophilia A
13.4.2. Hemophilia B
13.4.3. Von Willebrand Disease
13.4.4. Others
13.5. Latin America Recombinant Plasma Protein Therapeutics Market Value Forecast, by Country/Sub-region, 2016–2026
13.5.1. Brazil
13.5.2. Mexico
13.5.3. Rest of Latin America
13.6. Latin America Recombinant Plasma Protein Therapeutics Market Attractiveness Analysis
13.6.1. By Drug Class
13.6.2. By Cell Line
13.6.3. By Indication
13.6.4. By Country/Sub-region
14. Middle East & Africa Recombinant Plasma Protein Therapeutics Market Analysis and Forecast
14.1. Introduction
14.1.1. Key Findings
14.2. Middle East & Africa Recombinant Plasma Protein Therapeutics Market Value Forecast, by Drug Class, 2016–2026
14.2.1. Recombinant Coagulation Factors
14.2.1.1. Recombinant Coagulation Factor VIII
14.2.1.2. Recombinant Coagulation Factor IX
14.2.1.3. Recombinant Coagulation Factor VIIa
14.2.1.4. Others
14.2.2. Human C1 Esterase Inhibitor
14.3. Middle East & Africa Recombinant Plasma Protein Therapeutics Market Value Forecast, by Cell Line, 2016–2026
14.3.1. Chinese Hamster Ovary (CHO) Cell Line
14.3.2. Baby Hamster Kidney (BHK) Cell Line
14.3.3. Human Embryonic Kidney (HEK) Cell Line
14.3.4. Others
14.4. Middle East & Africa Recombinant Plasma Protein Therapeutics Market Value Forecast, by Indication, 2016–2026
14.4.1. Hemophilia A
14.4.2. Hemophilia B
14.4.3. Von Willebrand Disease
14.4.4. Others
14.5. Middle East & Africa Recombinant Plasma Protein Therapeutics Market Value Forecast, by Country/Sub-region, 2016–2026
14.5.1. GCC Countries
14.5.2. South Africa
14.5.3. Rest of Middle East & Africa
14.6. Middle East & Africa Recombinant Plasma Protein Therapeutics Market Attractiveness Analysis
14.6.1. By Drug Class
14.6.2. By Cell Line
14.6.3. By Indication
14.6.4. By Country/Sub-region
15. Competitive Landscape
15.1. Market Player – Competition Matrix (By Tier and Size of companies)
15.2. Market Share Analysis By Company (2016)
15.3. Company Profiles
15.3.1. CSL Limited
15.3.1.1. Company Details
15.3.1.2. Products Portfolio
15.3.1.3. Financial Overview
15.3.1.4. Strategic Overview
15.3.1.5. SWOT Analysis
15.3.2. Shire (Takeda Pharmaceutical Company Limited)
15.3.2.1. Company Details
15.3.2.2. Products Portfolio
15.3.2.3. Financial Overview
15.3.2.4. Strategic Overview
15.3.2.5. SWOT Analysis
15.3.3. Octapharma
15.3.3.1. Company Details
15.3.3.2. Products Portfolio
15.3.3.3. Financial Overview
15.3.3.4. Strategic Overview
15.3.3.5. SWOT Analysis
15.3.4. Novo Nordisk A/S
15.3.4.1. Company Details
15.3.4.2. Products Portfolio
15.3.4.3. Financial Overview
15.3.4.4. Strategic Overview
15.3.4.5. SWOT Analysis
15.3.5. Bayer AG
15.3.5.1. Company Details
15.3.5.2. Products Portfolio
15.3.5.3. Financial Overview
15.3.5.4. Strategic Overview
15.3.5.5. SWOT Analysis
15.3.6. Pfizer Inc.
15.3.6.1. Company Details
15.3.6.2. Products Portfolio
15.3.6.3. Financial Overview
15.3.6.4. Strategic Overview
15.3.6.5. SWOT Analysis
15.3.7. Bioverativ Therapeutics, Inc. (Sanofi)
15.3.7.1. Company Details
15.3.7.2. Products Portfolio
15.3.7.3. Financial Overview
15.3.7.4. Strategic Overview
15.3.7.5. SWOT Analysis
15.3.8. Aptevo Therapeutics
15.3.8.1. Company Details
15.3.8.2. Products Portfolio
15.3.8.3. Financial Overview
15.3.8.4. Strategic Overview
15.3.8.5. SWOT Analysis
15.3.9. Pharming Group NV
15.3.9.1. Company Details
15.3.9.2. Products Portfolio
15.3.9.3. Financial Overview
15.3.9.4. Strategic Overview
15.3.9.5. SWOT Analysis
Table 01 Global Recombinant Plasma Protein Therapeutics Market, New Product Launch and Regulatory Approvals, 2017?2018
Table 02 Global Recombinant Plasma Protein Therapeutics Market, New Product Launch and Regulatory Approvals, 2015?2017
Table 03 Global Recombinant Plasma Protein Therapeutics Market, New Product Launch and Regulatory Approvals, 2014?2015
Table 04 Global Recombinant Plasma Protein Therapeutics Market Value (US$ Mn) Forecast, by Drug Class, 2016–2026
Table 05 Global Recombinant Plasma Protein Therapeutics Market Value (US$ Mn) Forecast, by Recombinant Coagulation Factors, 2016–2026
Table 06 Global Recombinant Plasma Protein Therapeutics Market Value (US$ Mn) Forecast, by Cell Line, 2016–2026
Table 07 Global Recombinant Plasma Protein Therapeutics Market Value (US$ Mn) Forecast, by Indication, 2016–2026
Table 08 Global Recombinant Plasma Protein Therapeutics Market Value (US$ Mn) Forecast, by Region, 2016–2026
Table 09 North America Recombinant Plasma Protein Therapeutics Market Value (US$ Mn) Forecast, by Drug Class, 2016–2026
Table 10 North America Recombinant Plasma Protein Therapeutics Market Value (US$ Mn) Forecast, by Recombinant Coagulation Factors, 2016–2026
Table 11 North America Recombinant Plasma Protein Therapeutics Market Value (US$ Mn) Forecast, by Cell Line, 2016–2026
Table 12 North America Recombinant Plasma Protein Therapeutics Market Value (US$ Mn) Forecast, by Indication, 2016–2026
Table 13 North America Recombinant Plasma Protein Therapeutics Market Value (US$ Mn) Forecast, by Country, 2016–2026
Table 14 Europe Recombinant Plasma Protein Therapeutics Market Value (US$ Mn) Forecast, by Drug Class, 2016–2026
Table 15 Europe Recombinant Plasma Protein Therapeutics Market Value (US$ Mn) Forecast, by Recombinant Coagulation Factors, 2016–2026
Table 16 Europe Recombinant Plasma Protein Therapeutics Market Value (US$ Mn) Forecast, by Cell Line, 2016–2026
Table 17 Europe Recombinant Plasma Protein Therapeutics Market Value (US$ Mn) Forecast, by Indication, 2016–2026
Table 18 Europe Recombinant Plasma Protein Therapeutics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2016–2026
Table 19 Asia Pacific Recombinant Plasma Protein Therapeutics Market Value (US$ Mn) Forecast, by Drug Class, 2016–2026
Table 20 Asia Pacific Recombinant Plasma Protein Therapeutics Market Value (US$ Mn) Forecast, by Recombinant Coagulation Factors, 2016–2026
Table 21 Asia Pacific Recombinant Plasma Protein Therapeutics Market Value (US$ Mn) Forecast, by Cell Line, 2016–2026
Table 22 Asia Pacific Recombinant Plasma Protein Therapeutics Market Value (US$ Mn) Forecast, by Indication, 2016–2026
Table 23 Asia Pacific Recombinant Plasma Protein Therapeutics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2016–2026
Table 24 Latin America Recombinant Plasma Protein Therapeutics Market Value (US$ Mn) Forecast, by Drug Class, 2016–2026
Table 25 Latin America Recombinant Plasma Protein Therapeutics Market Value (US$ Mn) Forecast, by Recombinant Coagulation Factors, 2016–2026
Table 26 Latin America Recombinant Plasma Protein Therapeutics Market Value (US$ Mn) Forecast, by Cell Line, 2016–2026
Table 27 Latin America Recombinant Plasma Protein Therapeutics Market Value (US$ Mn) Forecast, by Indication, 2016–2026
Table 28 Latin America Recombinant Plasma Protein Therapeutics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2016–2026
Table 29 Middle East & Africa Recombinant Plasma Protein Therapeutics Market Value (US$ Mn) Forecast, by Drug Class, 2016–2026
Table 30 Middle East & Africa Recombinant Plasma Protein Therapeutics Market Value (US$ Mn) Forecast, by Recombinant Coagulation Factors, 2016–2026
Table 31 Middle East & Africa Recombinant Plasma Protein Therapeutics Market Value (US$ Mn) Forecast, by Cell Line, 2016–2026
Table 32 Middle East & Africa Recombinant Plasma Protein Therapeutics Market Value (US$ Mn) Forecast, by Indication, 2016–2026
Table 33 Middle East & Africa Recombinant Plasma Protein Therapeutics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2016–2026